Why Is CASI Pharmaceuticals, Inc. Ordinary Shares (CASI) Stock Down 66.2% Today?

CASI Pharmaceuticals (CASI) stock got crushed. The biotech plunged 66.2% to $0.2585 on 3.77M shares traded—191x the 30-day average volume of 19,740 shares. The trigger: a buyout offer for the company's China business. Traders are spooked by the deal terms and what it signals about CASI's standalone value. Here's why CASI is down today and what comes next.

What's Driving CASI Stock Down Today

CASI disclosed it received a non-binding buyout offer for its China operations. That's the headline catalyst. But the market's reading this as a red flag: if the China business is being shopped separately, management may be signaling the core U.S. operations aren't firing on enough cylinders to sustain the company as-is.

The 66% washout suggests investors are pricing in significant downside risk to deal valuation. When a small-cap biotech starts auctioning off geography-specific assets, it typically means cash runway concerns or disappointing pipeline progress. CASI's main product, EVOMELA (melphalan) injection for conditioning pre-autologous stem cell transplant, faces competition and reimbursement headwinds. Separating the China revenue stream could indicate management is trying to maximize whatever value remains.

Context matters here: CASI closed yesterday at $0.80, putting today's $0.2585 print at a brutal loss from even recent lows. The stock had been grinding lower on negative sentiment. This buyout offer confirmation is the match that lit the powder keg. Volume exploding 191x average confirms panic selling, not normal trading.

CASI Stock Key Levels to Watch

Current price sits at $0.2585. That's now support if the stock stabilizes—a potential floor for oversold bounce traders. Resistance is the previous close of $0.80, though that feels miles away given today's damage.

The day's range is $0.2368 to $0.3749. The $0.2368 low from this morning is now the intraday pivot. A break below $0.20 would suggest the stock is pricing in distressed-level scenarios. Above $0.35, weak shorts might cover and trigger a bounce into close.

52-week context: we'd need recent highs/lows to nail the technical picture, but at $0.2585, CASI is trading near penny stock territory. Once a stock enters sub-$1 range on this kind of volume and volatility, technicals break down fast. Support becomes whatever panic sellers push it down to. Resistance becomes wherever exhausted sellers can finally cover.

Volume analysis: 3.77M shares vs 19,740 average is utterly absurd. That's not institutional buying or short covering—that's pure forced liquidation and panic. When volume explodes 190x average on a 66% drop, expect violent whipsaws tomorrow as shorts take profits and any technical bounces draw fresh selling.

What Analysts Say About CASI Stock

HC Wainwright maintained a Buy rating on CASI as of November 2023, though that guidance predates today's bombshell. Consensus data from earlier periods showed support for the biotech story, but a 66% gap-down on deal uncertainty obliterates consensus overnight.

The Buy call was likely predicated on EVOMELA uptake and pipeline optionality. That thesis just got nuked by the China business buyout offer, which signals the company may be in survival mode. If the China segment is being auctioned off at a bargain valuation, it raises hard questions about CASI's total enterprise value.

Current analyst consensus is effectively worthless until firms refresh their models post-announcement. Expect downgrades to follow. Price targets built on a functioning China revenue stream are now obsolete. Any analyst maintaining a Buy here without updated assumptions is asleep at the wheel.

What's Next for CASI Stock

Specific Catalysts: Watch for deal closure details. CASI will need to disclose valuation, timeline, and earnout terms. If the China unit sells at a rock-bottom price, holders should prepare for equity dilution or restructuring announcements. Next earnings report will be critical—expect guidance cuts if China revenue gets stripped out.

Bull Case: The China sale could raise enough cash to fund EVOMELA commercialization and pipeline advancement in the U.S. If CASI can stabilize on $0.25–$0.30 and prove EVOMELA has stronger uptake than feared, this could bounce hard to $0.50+. Biotech washouts attract dip-buyers when valuation gets absurd enough.

Bear Case: China sale valuation comes in even lower than feared, forcing capital raise that dilutes existing shares 50%+. CASI could spiral into delisting risk if the stock can't hold above $1 for more than 30 days. If EVOMELA's commercial traction doesn't materialize post-sale, the company runs out of cash and equity becomes worthless.

Next catalyst: Deal announcement details, which should come within weeks. Options market is pricing another 10–15% move. Watch for any SEC filings or press releases clarifying buyer identity and valuation metrics. Until we know if China sold for $50M or $5M, this stock remains a speculation play with binary risk.

Frequently Asked Questions

Why is CASI stock down 66% today?
CASI Pharmaceuticals disclosed a non-binding buyout offer for its China business. The market interpreted this as a signal that standalone U.S. operations aren't strong enough, triggering panic selling. Traders fear the China sale will be priced low and force equity dilution or restructuring.

Is CASI stock a buy right now?
This is a high-risk speculation play, not a buy. CASI is now trading at penny stock levels on massive uncertainty around deal valuation and cash runway. HC Wainwright's previous Buy rating predates today's news and is likely being re-evaluated. Wait for deal details and updated analyst models before considering any position.

What is CASI stock trading at?
CASI is at $0.2585 after today's 66.2% crash from $0.80. Day range was $0.2368 to $0.3749 on 3.77M shares—191x average volume. The stock is now in penny stock territory with extreme volatility.

What is CASI's market cap now?
Market cap shows $0.0B given the collapsed share price. The company's enterprise value has effectively erased today. Any valuation is now binary dependent on China deal closure and remaining cash reserves.

When will CASI announce deal details?
CASI hasn't specified a timeline, but expect details within 4–6 weeks. Watch SEC filings, investor relations updates, and press releases for buyer identity, valuation, timing, and earnout terms. That's your next real catalyst.

The Bottom Line

CASI stock got destroyed on a China business buyout offer that signals deeper problems at the biotech. The 66% washout on 191x average volume screams panic, not rational selling. Until deal details emerge, CASI remains a binary bet with distressed-level risk.

Position sizing matters if you're even thinking about this. Risk management is mandatory. This isn't a company; it's a lottery ticket on deal valuation and cash preservation. Wait for the China deal specifics before making any move.